This site is for US residents only

GEOMETRYmono-1: Phase II Trial of INC280

Capmatinib (INC280)

A Phase II study for people with non-small cell lung cancer (NSCLC) that harbors a MET mutation and/or amplification

Call me back

For more information about Signature trials, enter your contact details and a representative will call you at your convenience.

*Required Information

*First Name
*Last Name
*Phone Number
*Zip Code
*Preferred time to call
*Time zone

Your email has been successfully sent

There was an error while sending your email

Contact a medical science liaison

Please enter your information below and a Novartis Medical Science Liaison will be in touch.

*Required Information

*First Name
*Last Name
*Phone Number
*Zip Code
Speciality

Your email has been successfully sent

There was an error while sending your email

Trial Goal

The goal of this study is to determine the safety and efficacy of oral cMET inhibitor Capmatinib (INC280) in adult patients with EGFR wild-type, advanced or metastatic non-small cell lung cancer (NSCLC) after 1 or 2 prior lines of systemic therapy.